Romidepsin (Romidepsin) Patent Expiration, LOE Window & CMS Spending

Romidepsin (Romidepsin) by Fresenius Kabi: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $1.6M 2024 CMS Part D & Medicaid spend, and $8,700 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorFresenius Kabi
FDA Application & PathwayN208574 (NDA)
Exclusivity / Cliff HorizonOff-Patent Uncontested (0 AB Generics)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.6M
2024 Medicare Part D Spend$386K
2024 Medicaid Spend$1.2M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($8,700 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.